Search clinical trials for: Sunitinib mFOLFOX6

Total 991 results

Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
Pfizer

Completed

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

Neoplasms | Colorectal Neoplasms

United States
Five Prime Therapeutics, Inc.

Completed

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (FIGHT)

Gastric Cancer | Gastrointestinal Cancer | Gastrointestinal Cancer Metastatic

United States
Five Prime Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

Gastric Cancer

United States, Spain, China, Italy, Korea, Republic of, Portugal, Taiwan, Japan, Turkey, France, Hungary, Thailand, Germany, Poland, Australia, Belgium, Romania, United Kingdom
Fudan University

Not yet recruiting

Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Colorectal Cancer | Liver Metastases

China
Pfizer

Completed

Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

Colorectal Neoplasms

Japan
Pfizer

Terminated

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Colorectal Neoplasms

United States, Denmark, Germany, Japan
University Health Network, Toronto
Pfizer

Completed

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma (SNIPP)

Pheochromocytoma | Paraganglioma

Canada, Netherlands
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Ain Shams University

Recruiting

the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Gastrointestinal Cancer

Egypt
MedImmune LLC

Withdrawn

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Microsatellite-stable Colorectal Cancer
Fudan University

Recruiting

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis (CANWATCH)

Colorectal Cancer | Adjuvant Chemotherapy

China
Xu jianmin

Unknown

Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer

Neoplasm Metastasis | Liver Neoplasms | Colorectal Neoplasms

China
Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
Cogent Biosciences, Inc.

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Metastatic Cancer | Advanced Gastrointestinal Stromal Tumors

United States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
AGO Study Group
Philipps University Marburg Medical Center; HSK Reasearch GmbH Wiesbaden

Completed

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

Platinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian Tube

Germany
Mothaffar Rimawi

Terminated

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (CRIZENT)

Breast Cancer

United States
Fujian Medical University Union Hospital

Recruiting

Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer

Rectal Cancer | Radiation Oncology

China
Martin-Luther-Universität Halle-Wittenberg
GALMED GmbH

Completed

TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) (AIO-KRK-0111)

Colorectal Cancer

Germany
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

Kidney Cancer

United States
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
Liz-Anne Lewsley
AstraZeneca; NHS Greater Glasgow and Clyde; University of Glasgow

Not yet recruiting

A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer (PRIME-RT)

Rectal Cancer | Rectal Neoplasms | Rectal Adenocarcinoma
Fudan University

Not yet recruiting

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
NRG Oncology
National Cancer Institute (NCI); Natera, Inc.

Recruiting

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Stage III Colon Cancer

United States, Canada
Pfizer

Completed

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Breast Neoplasms

United States
Pfizer

Completed

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene

Gastrointestinal Stromal Tumors

Korea, Republic of
California Pacific Medical Center Research Institute
Pfizer; University of California, San Francisco

Completed

Clinical Trial of Sutent to Treat Metastatic Melanoma

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma

Canada
Pfizer

Completed

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

United States, Czechia, France
Asan Medical Center

Completed

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

Metastatic Renal Cell Carcinoma

Korea, Republic of
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

Canada, United States
AVEO Pharmaceuticals, Inc.

Completed

Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

Colorectal Cancer | Gastrointestinal Cancer

Netherlands
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Recurrent Uterine Sarcoma | Uterine Leiomyosarcoma

United States
Case Comprehensive Cancer Center

Completed

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent... and other conditions

United States
Centre Hospitalier Universitaire Dijon

Recruiting

CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II (CIRCULATE)

Patients With Resected Stage II Colon Cancer

France
Peking Union Medical College Hospital

Unknown

FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer (FOLFOX6)

Gastric Cancer | Surgery | Effects of Chemotherapy

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Exelixis

Active, not recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract | Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada
Amgen

Completed

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Cervical Adenosquamous Cell Carcinoma

Canada
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
Zhou Fuxiang
Xiangya Hospital of Central South University; Henan Cancer Hospital; Hubei Cancer... and other collaborators

Recruiting

Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Metastatic Colorectal Cancer

China
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Adult Diffuse Large Cell Lymphoma

Canada
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Yamagata University

Unknown

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma (CROSS-J-RCC)

Metastatic Renal Cell Carcinoma

Japan

Search clinical trials for: Sunitinib mFOLFOX6

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations